Institute of Health Carlos III
Develop epidemiological and entomological methods to assess verification of transmission interruption of Onchocerciasis in Equatorial Guinea- Africa
After two decades of onchocerciasis control activities in Bioko island, transmission is expected to be interrupted. This study aims to demonstrate that WHO criteria to verify transmission interruption have been met. It also aims to standardize the reading of RDTs, particularly the FTS and Ov16, and reduce the potential for human error.
Preliminary Study Findings:
A cross-sectional study was conducted from September 2016 to January 2017. Participants were 5- to 9-year-old school children. Onchocerciasis/lymphatic Filariasis (LF, only in endemic districts) rapid diagnostic tests (RDTs) were performed. Blood spots were collected from RDT positive children and 10 percent of the RDT negatives to determine Ov16 and Wb123 IgG4 antibodies through enzyme-linked immunosorbent assay (ELISA). Skin snips were collected from RDT positives. Filarial detection was performed by PCR in positives and indeterminate sera. Black fly collection was carried out in traditional breeding sites. A total of 7,052 children, ranging from 5 to 9 years of age, were included in the study. Four children (0.06%) were Ov16 IgG4 RDT positives, but negative by ELISA Ov16, while 6 RDT negative children tested positive by ELISA. A total of 1,230 children from the Riaba and Baney districts were tested for LF. One child was Wb123 RDT positive (0.08%), but ELISA negative, while 3 RDT negative children were positive by Wb123 ELISA. All positive samples were negative by PCR for onchocerciasis and LF (in blood spot and skin snip). All fly collections and larval prospections in the traditional catching and prospection sites were negative.
Read more in Herrador et al.: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006471
Beta-lactam containing regimen for the shortening of Buruli ulcer disease therapy: comparison of 8 weeks standard therapy (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate therapy [RC8 vs. RCA4].
The research question to be addressed by this clinical study is whether co-administration of amoxicillin/clavulanate with current standard (rifampicin plus clarithromycin) therapy could reduce Buruli ulcer (BU) treatment from 8 to 4 weeks (RC8 vs. RCA4).